Current Research Studies

Efficacy, safety, and pharmacokinetics of vericiguat in pediatric participants with heart failure due to left ventricular systolic dysfunction

VALOR

Phase: II/III
Clinicaltrials.gov ID: NCT06428383

What is the goal of the study?

Phase 2/3 adaptive randomized, placebo-controlled, parallel-group, multisite, double-blind study of vericiguat in pediatric participants with HF due to LV systolic dysfunction consistent with dilated cardiomyopathy and NT-proBNP level between 500 and 6000 pg/mL within 30 days before randomization.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Yuk Law
Study Team Member: Annabeth Evans, [email protected]